At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Janthinobacterium lividumdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Study Protocol Number DBI-201- Open Label, Single-dose, Dose Escalating Evaluation of the Safety and Tolerability of DBI-001 in Patients With Tinea Pedis
In Brief
A Phase 2 clinical trial evaluating Janthinobacterium lividum for Tinea Pedis. Completed, enrolled 12 participants across 1 site.
Detailed Summary
This is an open-label, single-dose, dose escalating evaluation of the safety and tolerability of three dose levels of DBI-001 in patients with Tinea pedis. The purpose of the current protocol is to establish the safety and tolerability of a single application of J. lividum to the feet of patients with proven T. pedis. In addition, the effect of J. lividum on the T. pedis will also be evaluated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTinea Pedis
CountriesDominican Republic
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartFeb 2019
Primary CompletionApr 2019
First PostedNov 2019
TodayJul 2026
First PostedNov 5, 2019
Enrollment StartFeb 19, 2019
Primary CompletionApr 30, 2019
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 6.7 years ago
Interventions
Janthinobacterium lividumdrug
Investigational Product